In the present study, we show that Nectin-2 is over-expressed in various cancers and that anti-Nectin-2 mAb can exert an in vivo anti-tumor effect on breast and ovarian cancer cells, which suggests the potential of Nectin-2 as a target for antibody therapy for cancer treatment. This evidence concerns the gene NECTIN2 and ovarian carcinoma.